BioNotebook: Juno's $134m Series B more than 3 VC deals combined

Juno Therapeutics continues to astound the biotechnology industry and the 2013 startup hasn't even reported any human clinical trial results, but the Seattle, Washington-based company has raised an eye-popping $310m in venture capital financing since its launch in December.

Juno Therapeutics continues to astound the biotechnology industry and the 2013 startup hasn't even reported any human clinical trial results, but the Seattle, Washington-based company has raised an eye-popping $310m in venture capital financing since its launch in December.

Juno was started with a $120m Series A round to finance the development of T cell-based immunotherapies (scripintelligence.com, 5...

More from Anti-infective

More from Therapeutic Category